Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil Consolidation for Ovarian Cancer
NCT00248248Phase 2Completed
- Sponsor
- Southeastern Gynecologic Oncology
- Start
- Oct 2005
- Primary completion
- Oct 2011
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Southeastern Gynecologic Oncology. Started Oct 2005; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00248248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248248.